(R)-2-(3-oxo-1-tosyl-1,2,3,4-tetrahydropyrazin-2-yl)acetic acid | 875126-57-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-(3-oxo-1-tosyl-1,2,3,4-tetrahydropyrazin-2-yl)acetic acid
• 英文别名: 2-[(3R)-4-(4-methylphenyl)sulfonyl-2-oxo-1,3-dihydropyrazin-3-yl]acetic acid
• CAS: 875126-57-1
• 化学式: C₁₃H₁₄N₂O₅S
• 分子量: 310.331
• InChiKey: OBAFWLYRYIEGGN-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-2-(3-oxo-1-tosyl-1,2,3,4-tetrahydropyrazin-2-yl)acetic acid 在 盐酸 、 三乙酰氧基硼氢化钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-[(3R)-4-(4-methylphenyl)sulfonyl-2-oxo-1,3-dihydropyrazin-3-yl]-N-[(4S)-1,3,3-trimethylpiperidin-4-yl]acetamide
  参考文献：
  名称：

  Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency

  摘要：

  In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.11.112
• 作为产物：
  描述：

  (R)-tert-butyl 4-(2,2-dimethoxyethylamino)-3-(4-methylphenylsulfonamido)-4-oxobutanoate 在 对甲苯磺酸 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 (R)-2-(3-oxo-1-tosyl-1,2,3,4-tetrahydropyrazin-2-yl)acetic acid
  参考文献：
  名称：

  Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency

  摘要：

  In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.11.112

文献信息

• 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use
  申请人：Askew C. Benny

  公开号：US20060025400A1

  公开（公告）日：2006-02-02

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和疾病，如炎症介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，药物组合物以及用于预防和治疗涉及疼痛、炎症等疾病和其他不适或情况的方法。该发明还涉及制备此类化合物的方法，以及在此类过程中有用的中间体。
• Bradykinin 1 Receptor Antagonists
  申请人：Zhu Jiawang

  公开号：US20090227601A1

  公开（公告）日：2009-09-10

  The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.

  该发明涵盖了新型化合物及其药学上可接受的衍生物，药物组合物以及治疗由B1布雷金因子受体介导的疾病的方法。
• 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use
  申请人：Amgen Inc.

  公开号：US07662811B2

  公开（公告）日：2010-02-16

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于治疗疼痛和疾病，如炎症介导的疾病具有有效性。本发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物、制药组合物以及用于预防和治疗涉及疼痛、炎症等疾病和其他疾病或病症的方法。本发明还涉及制造这些化合物的过程以及在这些过程中有用的中间体。
• WO2007/67629
  申请人：——

  公开号：——

  公开（公告）日：——
• 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS
  申请人：Amgen Inc.

  公开号：EP1817294A1

  公开（公告）日：2007-08-15